Pharmaust Limited (ECQ0) Price & Analysis

Compare

3 Followers

ECQ0 Stock Chart & Stats

€0.04

€0.00(0.00%)

At close: Jan 08 4:00 PM EST

€0.04

€0.00(0.00%)

Day’s Range― - ―

52-Week Range€0.04 - €0.10

Previous CloseN/A

Volume0.00

Average Volume (3M)999.00

Market Cap

€34.43M

Enterprise Value€51.73M

Total Cash (Recent Filing)€9.72M

Total Debt (Recent Filing)€0.00

Price to Earnings (P/E)―

Beta1.25

Next Earnings

Aug 28, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)>-0.01

Shares Outstanding698,628,660

10 Day Avg. Volume2,225

30 Day Avg. Volume999

Financial Highlights & Ratios

PEG Ratio-0.08

Price to Book (P/B)25.24

Price to Sales (P/S)0.00

P/FCF Ratio-4.98

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

€0.17

Price Target Upside331.25% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering1

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Debt-free Balance SheetHaving zero reported debt materially reduces near-term refinancing and interest-cost risk, preserving operational flexibility. For a cash-burning developer, low leverage makes any necessary fundraising less encumbered by debt covenants and lowers fixed obligations over the next 2–6 months.

Specialized Veterinary R&D And CommercializationA focused business model across companion animals and livestock concentrates expertise in veterinary therapeutics and regulatory pathways. This structural specialization supports durable market positioning, repeatable product development processes, and access to resilient animal-health demand over a multi-month horizon.

Cash Outflows Align With Reported LossesOperating cash flow that tracks accounting losses improves the transparency and predictability of funding needs. This alignment reduces risk of hidden working-capital shortfalls and allows more reliable runway estimates and planning for financing or cost actions across the next 2–6 months.

Bears Say

Revenue Fell To ZeroA collapse to zero revenue signals loss of commercial momentum and undermines any near-term prospect of organic funding from sales. Without product sales, the company must rely on external financing or major partnerships, increasing execution and dilution risk over the coming months.

Accelerating Cash BurnA sharp increase in cash burn shortens the runway and raises the probability of near-term capital raises. Persistent negative operating and free cash flow at this scale materially increases funding risk, constraining strategic options and forcing either rapid cost reductions or external financing.

Severe Equity ErosionRapid decline in shareholder equity erodes the capital buffer available to absorb losses and increases likelihood of dilution or distressed financing. Reduced equity weakens balance-sheet resilience and limits the firm's ability to fund R&D or regulatory activities without dilutive capital raises.

Pharmaust Limited News

Neurizon CEO Michael Thurn Resigns as Biotech Launches Global Search for Successor

Pharmaust Limited ( ($AU:NUZ) ) has provided an announcement. Neurizon Therapeutics has announced that Managing Director and Chief...

2d ago

Neurizon Expands NUZ-001 Huntington’s Disease Data at ASENT 2026

Pharmaust Limited ( ($AU:NUZ) ) just unveiled an update. Neurizon Therapeutics has presented new preclinical data on its...

13d ago

Neurizon Therapeutics Options Lapse, Trimming Potential Equity Overhang

An update from Pharmaust Limited ( ($AU:NUZ) ) is now available. Neurizon Therapeutics Limited has informed the market...

14d ago

Neurizon Draws First $5m Tranche to Advance ALS Drug Trial

Pharmaust Limited ( ($AU:NUZ) ) has shared an update. Neurizon Therapeutics has drawn down the first $5 million...

19d ago

Neurizon Taps A$5m in Convertible Note Funding From Obsidian

Pharmaust Limited ( ($AU:NUZ) ) has issued an announcement. Neurizon Therapeutics has issued a cleansing notice ahead of...

19d ago

Neurizon issues 10m shares under convertible note, affirms compliance and disclosure

Pharmaust Limited ( ($AU:NUZ) ) has provided an update. Neurizon Therapeutics has issued 10,000,000 fully paid ordinary shares...

19d ago

Neurizon Begins Pivotal NUZ-001 Dosing in HEALEY ALS Platform Trial

Pharmaust Limited ( ($AU:NUZ) ) just unveiled an update. Neurizon Therapeutics has begun dosing the first participant with...

20d ago

Neurizon Narrows Half-Year Loss as Other Income Jumps and Net Assets Strengthen

Pharmaust Limited ( ($AU:NUZ) ) has issued an announcement. Neurizon Therapeutics Limited reported a sharply lower half-year loss...

21d ago

Neurizon Publishes General Meeting Results and Enhances Investor Engagement

The latest update is out from Pharmaust Limited ( ($AU:NUZ) ). Neurizon Therapeutics Limited has released the results...

26d ago

Neurizon Therapeutics Issues Heavily Qualified General Meeting Presentation

An announcement from Pharmaust Limited ( ($AU:NUZ) ) is now available. Neurizon Therapeutics has released a general meeting...

26d ago

ECQ0 FAQ

What was Pharmaust Limited’s price range in the past 12 months?

Pharmaust Limited lowest stock price was €0.04 and its highest was €0.10 in the past 12 months.

What is Pharmaust Limited’s market cap?

Pharmaust Limited’s market cap is €34.43M.

When is Pharmaust Limited’s upcoming earnings report date?

Pharmaust Limited’s upcoming earnings report date is Aug 28, 2026 which is in 164 days.

How were Pharmaust Limited’s earnings last quarter?

Pharmaust Limited released its earnings results on Feb 24, 2026. The company reported -€0.007 earnings per share for the quarter, missing the consensus estimate of N/A by -€0.007.

Is Pharmaust Limited overvalued?

According to Wall Street analysts Pharmaust Limited’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Pharmaust Limited pay dividends?

Pharmaust Limited does not currently pay dividends.

What is Pharmaust Limited’s EPS estimate?

Pharmaust Limited’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Pharmaust Limited have?

Pharmaust Limited has 698,628,660 shares outstanding.

What happened to Pharmaust Limited’s price movement after its last earnings report?

Pharmaust Limited reported an EPS of -€0.007 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 8.333%.

Which hedge fund is a major shareholder of Pharmaust Limited?

Currently, no hedge funds are holding shares in DE:ECQ0

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Pharmaust Limited Stock Smart Score

Neutral

Fundamentals

Return on Equity

-254.33%

Trailing 12-Months

Asset Growth

-6.22%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Pharmaust Limited

Neurizon Therapeutics Limited, a clinical stage biotechnology company, develops therapeutics for neurodegenerative diseases. The company develops drug discovery intellectual property for the treatment of neurological diseases. Its lead candidate is NUZ-001, a small molecule drug which is in Phase II clinical trials for the treatment of amyotrophic lateral sclerosis, as well as to treat other neurodegenerative diseases. The company was formerly known as PharmAust Limited and changed its name to Neurizon Therapeutics Limited in October 2024. Neurizon Therapeutics Limited was incorporated in 2000 and is based in Melbourne, Australia.

Pharmaust Limited (ECQ0) Earnings & Revenues

Historic Earnings Reports

ECQ0 Stock 12 Month Forecast

Average Price Target

€0.17

▲(331.25% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"0":"€0","1":"€1","-1":"-€1","-0.5":"-€0.5","0.5":"€0.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":0.17249820000000002,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€0.17</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":0.17249820000000002,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€0.17</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":0.17249820000000002,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€0.17</span>\n  </div></div>","useHTML":true}}],"tickPositions":[-1,-0.5,0,0.5,1],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jun<br/>2025","6":"Sep<br/>2025","9":"Dec<br/>2025","12":"Mar<br/>2026","25":"Mar<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.048,0.05757678461538462,0.06715356923076923,0.07673035384615384,0.08630713846153847,0.09588392307692309,0.1054607076923077,0.11503749230769232,0.12461427692307693,0.13419106153846155,0.14376784615384616,0.15334463076923077,0.1629214153846154,{"y":0.17249820000000002,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.048,0.05757678461538462,0.06715356923076923,0.07673035384615384,0.08630713846153847,0.09588392307692309,0.1054607076923077,0.11503749230769232,0.12461427692307693,0.13419106153846155,0.14376784615384616,0.15334463076923077,0.1629214153846154,{"y":0.17249820000000002,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.048,0.05757678461538462,0.06715356923076923,0.07673035384615384,0.08630713846153847,0.09588392307692309,0.1054607076923077,0.11503749230769232,0.12461427692307693,0.13419106153846155,0.14376784615384616,0.15334463076923077,0.1629214153846154,{"y":0.17249820000000002,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":0.071,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.063,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.054,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.07,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.075,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.088,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.075,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.058,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.073,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.052,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.044,"date":1767225600000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":0.047,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.048,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >